For the quarter ended March 2025, Ionis Pharmaceuticals (IONS) reported revenue of $132 million, up 10.9% over the same period last year. EPS came in at -$0.75, compared to -$0.98 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $120.16 million, representing a surprise of +9.86%. The company delivered an EPS surprise of +32.43%, with the consensus EPS estimate being -$1.11.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Commercial revenue- SPINRAZA royalties: $48 million versus $43.02 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +26.3% change.
• Revenue- Total commercial revenue: $76 million compared to the $66.61 million average estimate based on eight analysts. The reported number represents a change of +28.8% year over year.
• Revenue- Total research and development revenue: $56 million versus the eight-analyst average estimate of $50.44 million.
• Revenue- Commercial revenue- WAINUA royalties: $9 million compared to the $9.89 million average estimate based on seven analysts.
• Revenue- Commercial revenue- Other commercial revenue- TEGSEDI and WAYLIVRA revenue, net: $6 million compared to the $6.93 million average estimate based on seven analysts. The reported number represents a change of -33.3% year over year.
• Revenue- Commercial revenue- Other commercial revenue: $6 million versus $12.73 million estimated by six analysts on average.
• Revenue- Research and development revenue- Collaborative agreement revenue: $46 million compared to the $37.10 million average estimate based on six analysts. The reported number represents a change of -6.1% year over year.
• Revenue- Research and development revenue- WAINUA joint development revenue: $10 million compared to the $10.05 million average estimate based on five analysts.

View all Key Company Metrics for Ionis Pharmaceuticals here>>>

Shares of Ionis Pharmaceuticals have returned +9.4% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research